Literature DB >> 33482972

CRISPR/Cas9 for the Clinician: Current uses of gene editing and applications for new therapeutics in oncology.

Julia Boland1,2, Elena Nedelcu3.   

Abstract

Precise genomic editing has given rise to treatments in previously untreatable genetic diseases and has led to revolutions in treatment for cancer. In the past decade, the discovery and development of clustered regularly interspaced short palindromic repeats (CRISPR) technologies has led to advances across medicine and biotechnology. Specifically, the CRISPR/Cas9 system has improved translational discovery and therapeutics for oncology across tumor types. In this review, we briefly summarize the history and development of CRISPR, explain CRISPR-Cas systems and CRISPR gene editing tools, highlight the development and application of CRISPR technologies for translational and therapeutic purposes in different oncologic tumors, and review novel treatment paradigms using CRISPR in immuno-oncology, including checkpoint inhibitors and chimeric antigen receptor T cell therapy.
Copyright © 2020 The Permanente Press. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33482972      PMCID: PMC7849285          DOI: 10.7812/TPP/20.040

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


  34 in total

1.  Identification of genes that are associated with DNA repeats in prokaryotes.

Authors:  Ruud Jansen; Jan D A van Embden; Wim Gaastra; Leo M Schouls
Journal:  Mol Microbiol       Date:  2002-03       Impact factor: 3.501

2.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors:  David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

3.  Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects.

Authors:  Bin Shen; Wensheng Zhang; Jun Zhang; Jiankui Zhou; Jianying Wang; Li Chen; Lu Wang; Alex Hodgkins; Vivek Iyer; Xingxu Huang; William C Skarnes
Journal:  Nat Methods       Date:  2014-03-02       Impact factor: 28.547

4.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

5.  Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.

Authors:  Justin Eyquem; Jorge Mansilla-Soto; Theodoros Giavridis; Sjoukje J C van der Stegen; Mohamad Hamieh; Kristen M Cunanan; Ashlesha Odak; Mithat Gönen; Michel Sadelain
Journal:  Nature       Date:  2017-02-22       Impact factor: 49.962

Review 6.  Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.

Authors:  Kaixian Zhang; Qianqian Yuan
Journal:  J Cancer Res Ther       Date:  2016-12       Impact factor: 1.805

7.  Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010.

Authors:  Rafael Meza; Clare Meernik; Jihyoun Jeon; Michele L Cote
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

8.  In vivo genome editing using Staphylococcus aureus Cas9.

Authors:  F Ann Ran; Le Cong; Winston X Yan; David A Scott; Jonathan S Gootenberg; Andrea J Kriz; Bernd Zetsche; Ophir Shalem; Xuebing Wu; Kira S Makarova; Eugene V Koonin; Phillip A Sharp; Feng Zhang
Journal:  Nature       Date:  2015-04-01       Impact factor: 49.962

Review 9.  Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.

Authors:  Claire F Friedman; Tracy A Proverbs-Singh; Michael A Postow
Journal:  JAMA Oncol       Date:  2016-10-01       Impact factor: 31.777

Review 10.  CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases.

Authors:  Faheem Ahmed Khan; Nuruliarizki Shinta Pandupuspitasari; Huang Chun-Jie; Zhou Ao; Muhammad Jamal; Ali Zohaib; Farhan Ahmed Khan; Muthia Raihana Hakim; Zhang ShuJun
Journal:  Oncotarget       Date:  2016-08-09
View more
  1 in total

Review 1.  Targeting Cancer with CRISPR/Cas9-Based Therapy.

Authors:  Katarzyna Balon; Adam Sheriff; Joanna Jacków; Łukasz Łaczmański
Journal:  Int J Mol Sci       Date:  2022-01-05       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.